Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival

European Urology

Volumn 65, Issue 6, 2014, Pages 1191-1197

  Danila, Daniel C ^a,b   Anand, Aseem ^a   Schultz, Nikolaus ^a   Heller, Glenn ^a   Wan, Mingliang ^a   Sung, Clifford C ^a   Dai, Charles ^a   Khanin, Raya ^a   Fleisher, Martin ^a   Lilja, Hans ^a,c   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Biomarker; Circulating tumor cells; Prostate cancer; Prostate specific markers

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MESSENGER RNA; TUMOR MARKER; DNA BINDING PROTEIN; FOXA1 PROTEIN, HUMAN; GRHL2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; HOXB13 PROTEIN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL COUNTING; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; GENE EXPRESSION ASSAY; GENETIC TRANSCRIPTION; HUMAN; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VALIDATION STUDY; BLOOD; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR EMBOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DNA-BINDING PROTEINS; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HOMEODOMAIN PROTEINS; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TISSUE KALLIKREINS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899522850     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.07.006     Document Type: Article

References (29)

1. T. Ashworth A case of cancer in which cells similar to those in the tumours were seen in the blood after death Aus Med J 14 1869 146 149
2. R.A. Ghossein, H.I. Scher, and W.L. Gerald et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications J Clin Oncol 13 1995 1195 1200
3. L.M. McShane, and D.F. Hayes Publication of tumor marker research results: the necessity for complete and transparent reporting J Clin Oncol 30 2012 4223 4232
4. L. Zhang, C.Y. Wang, and R. Yang et al. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis Urol Oncol 26 2008 634 640
5. D.C. Danila, A. Anand, and C.C. Sung et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate Eur Urol 60 2011 897 904
6. K. Pantel, R.H. Brakenhoff, and B. Brandt Detection, clinical relevance and specific biological properties of disseminating tumour cells Nat Rev Cancer 8 2008 329 340
7. D.C. Danila, M. Fleisher, and H.I. Scher Circulating tumor cells as biomarkers in prostate cancer Clin Cancer Res 17 2011 3903 3912
8. D.R. Shaffer, M.A. Leversha, and D.C. Danila et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer Clin Cancer Res 13 2007 2023 2029
9. D.C. Danila, G. Heller, and G.A. Gignac et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin Cancer Res 13 2007 7053 7058
10. J.S. de Bono, H.I. Scher, and R.B. Montgomery et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer Clin Cancer Res 14 2008 6302 6309
11. H.I. Scher, X. Jia, and J.S. de Bono et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data Lancet Oncol 10 2009 233 239
12. H. Scher, G. Heller, and A. Molina et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract LBA4517] J Clin Oncol 29 suppl 2011
13. D.C. Danila, K. Pantel, M. Fleisher, and H.I. Scher Circulating tumors cells as biomarkers: progress toward biomarker qualification Cancer J 17 2011 438 450
14. X. Liu, X. Yu, D.J. Zack, H. Zhu, and J. Qian TiGER: a database for tissue-specific gene expression and regulation BMC Bioinformatics 9 2008 271
15. B.S. Taylor, N. Schultz, and H. Hieronymus et al. Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
16. A.I. Su, M.P. Cooke, and K.A. Ching et al. Large-scale analysis of the human and mouse transcriptomes Proc Natl Acad Sci U S A 99 2002 4465 4470
17. C. Wu, C. Orozco, and J. Boyer et al. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources Genome Biol 10 2009 R130
18. H.I. Scher, M. Eisenberger, and A.V. D'Amico et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 22 2004 537 556
19. W.J. Allard, J. Matera, and M.C. Miller et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases Clin Cancer Res 10 2004 6897 6904
20. M. Gonen, and G. Heller Concordance probability and discriminative power of proportional hazards regression Biometrika 92 2005 965 970
21. H. Lilja, D. Ulmert, and A.J. Vickers Prostate-specific antigen and prostate cancer: prediction, detection and monitoring Nat Rev Cancer 8 2008 268 278
22. C.M. Ewing, A.M. Ray, and E.M. Lange et al. Germline mutations in HOXB13 and prostate-cancer risk N Engl J Med 366 2012 141 149
23. J. Gerhardt, M. Montani, and P. Wild et al. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer Am J Pathol 180 2012 848 861
24. C.E. Barbieri, S.C. Baca, and M.S. Lawrence et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat Genet 44 2012 685 689
25. C.S. Grasso, Y.M. Wu, and D.R. Robinson et al. The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
26. S. Belikov, C. Oberg, T. Jaaskelainen, V. Rahkama, J.J. Palvimo, and O. Wrange FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide) Mol Cell Endocrinol 365 2013 95 107
27. X. Kang, W. Chen, R.H. Kim, M.K. Kang, and N.H. Park Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells Oncogene 28 2009 565 574
28. Guidance for industry. E16 biomarkers related to drug or biotechnology product development: context, structure, and format of qualification submissions. August 2011. US Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM267449.pdf.
29. 510(k) premarket notification [CellSearch]. US Food and Drug Administration Web site. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cfpmn/pmn.cfm?ID=26483. Updated July 1, 2013.